Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the stock in a transaction on Wednesday, May 17th. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $10,257.50. Following the completion of the acquisition, the director now owns 2,750 shares of the […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) CFO Michael Celano purchased 5,000 shares of the stock in a transaction dated Wednesday, May 17th. The stock was bought at an average cost of $3.73 per share, with a total value of $18,650.00. Following the completion of the purchase, the chief financial officer now owns 112,746 shares […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was acquired at an average price of $3.73 per share, with a total value of $10,257.50. Following the purchase, the director now directly owns 2,750 shares in the company, […]
Larimar Therapeutics, Inc. announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich s. | May 16, 2023
BALA CYNWYD, Pa. — BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. on Monday reported a loss of $6.5 million in its first quarter. On a per-share basis, the Bala Cynwyd,. | May 15, 2023